ASTRAZENECA PLC

Insider buying by AstraZeneca’s SVP signals confidence in its undervalued stock, robust pipeline, and AI‑driven growth—an insider‑backed cue for investors to watch for upside.

Insider buying surge at AstraZeneca shows execs believe the stock’s undervalued, with a potential NHS deal for Enhertu boosting future earnings. Click to learn how this could impact your portfolio.